Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/p/C4ggwWnr9X4/ Novo Nordisk, the Danish manufacturer of the diabetes drug semaglutide, repurposed for weight loss and branded as Wegovy and Ozempic, is once again screaming a warning to all those who are searching for this drug in a market where it is in very short supply.  While these warnings have been coming from the company and the FDA since late last year, Novo is now working with multiple countries as well as the US to stem the tide of counterfeit and dangerous semaglutide copycats.  These fakes are circulating in 16 or more countries, and they can be dangerous.   Some of the fakes deliver inaccurate levels of semaglutide from defective dispensers, and that leads to unpredictable and inaccurate doses that trigger life-threatening drops in blood sugar.  In other cases, counterfeits are created by compounding pharmacies that use raw semaglutide obtained from questionable sources around the world.  Lilly has found bacteria, other impurities, and non-medicinal chemical